Skip to main content

January 2017

 

 

academics

 

Clinical research courses

Requirement of Junior Research Fellow in Agharkar Research Institute (ARI)

Agharkar Research Institute (ARI) is an autonomous, grant-in-aid research institute of the Department of Science and Technology (DST), Goverment of India. It was established in 1946 by the Maharashtra Association for the Cultivation of Science as MACS Research Institute and renamed as ARI in 1992 in honour and memory of its founder Director, late Professor S.P. Agharkar.

Post: Junior Research Fellow

Vacancy for Lecturer at National Institute of Pharmaceutical Education and Research

The National Institute of Pharmaceutical Education and Research (NIPER) has been created as a centre of excellence for higher education, research and development in pharmaceutical sciences. NIPER, Rae Bareli at ITI campus, Rae Bareli under the mentor Institute of CSIR - Central Drug Research Institute, Lucknow invites applications for eligible candidates for following positions on purely temporary basis on contract initially for a period of 1 year which can be extended further. The selected candidates shall have no claim for regularization against any regular post either in NIPER or CDRI.

Post : Lecturer - 1 (One) (ST)

Job for M.Pharm, M.Sc, B.Pharm, B.Sc at Coral Drugs

Coral Drugs, headquartered in New Delhi, India, is an integrated, research-based international pharmaceutical company that produces a wide range of high-quality, affordable active drug ingredients. With a team of dedicated scientists, Coral's R&D department provides efficient processes for off-patent products. Our goal is to maximize on the production of active ingredients by discovering new ways to manufacture, without compromising quality. Having clients all over the world, we assume a great level of corporate responsibility. Adhering to quality production standards across the globe, Coral Drugs takes pride in being a true international supplier of high-quality pharmaceuticals.

Work as Associate Technical Lead in BioClinica

As pharmaceutical companies embraced clinical trial technology, Bio-Imaging's leaders sought to expand their service portfolio to offer customers a comprehensive suite of clinical trial management solutions. This vision inspired the acquisition of Phoenix Data Systems in 2008, a growing provider of eClinical solutions which had been in business since 1997. With a fresh start and a new direction, the expanded company was re-branded as Bioclinica in 2009. Over the next several years, Bioclinica continued to build its services platform by combining a mix of in-house technological innovation with a number of strategic acquisitions.

Post: Associate Technical Lead

Opening for QC Chemist at Clariant

Clariant is a globally leading specialty chemicals company, based in Muttenz near Basel/Switzerland. On 31 December 2015 the company employed a total workforce of 17 213. In the financial year 2015, Clariant recorded sales of CHF 5.807 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant's corporate strategy is based on five pillars: increase profitability, reposition portfolio, add value with sustainability, foster innovation and R&D, and intensify growth.

Post : QC Chemist

Job Opening for Clinical Research Associate in PPD Pharma

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 32 countries and more than 9,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients

Post: Clinical Research Associate

Job for Manager RA at Novartis

Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post : Manager RA, GDD - India

CINNAMON: A MAGICAL DRUG

{ DOWNLOAD AS PDF }

ABOUT AUHTOR
Pranav Nayak B*
Srinivas college of pharmacy,
Mangalore, Karnataka India,
*nayak.pranav10@gmail.com

 

ABSTRACT:
Cinnamon is used as a spice in our day to day life. It is aromatic. It is principally employed in cookery as a condiment and flavoring agent. It has been acquainted as one of the healthiest spices and has medicinal activity. When it is checked for chemical constituents it reveals phenolic flavonoid and carotenoid contents. They contain rich amount of polyphenols which are powerful antioxidants. It inhibits the growth of certain bacteria and fungi. It helps to reduce the blood glucose by increasing insulin in the body by the mechanism of resisting insulin depletion. It interferes with carbohydrate digesting enzyme and reduces degradation of carbohydrate as a result of which it decreases entry of glucose from intestine to blood stream. It reduces the growth of cancer cells. ‘N’ number of pharmacological investigationsconfirmed that the ability of this plant is to exhibit hepatoprotective, neuroprotective and cardioprotective action. This present article will provide you with detailed information on the most of the aspects of cinnamon.

OmniActive Health Technologies Ltd. announced that it has acquired 85 per cent stake, and has entered into definitive agreements to acquire the balance stake, in Bangalore-based leading health and nutrition active natural ingredients player Indfrag Ltd (Indfrag). The acquisition includes all products related to Indfrag’s Food and Nutrition business. 

This is in line with OmniActive’s programme to create global partnerships which help expand the portfolio of high quality authenticated ingredients for the dietary supplement and functional food industries.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company, announced results from AbbVie’s phase 3 CERTAIN-1 study of 8 weeks of treatment with AbbVie’s investigational, pan-genotypic, ribavirin (RBV)-free regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in Japanese patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection without cirrhosis. Top-line results from the study demonstrated 99 per cent (n=105/106) of patients without cirrhosis, who represent the majority of HCV patients, and without the Y93H variant, achieved sustained virologic response at 12 weeks after treatment (SVR12). The one patient who did not reach SVR12 in this intent to treat (ITT) population was lost to follow-up. All 23 patients with the Y93H variant were assigned to the G/P arm of this comparator study, and 100% achieved SVR12.